做爰xxxⅹ性生交,色屁屁影院免费观看,亚洲午夜高清国产拍在线观看,亲嘴揉胸口激烈视频,中文字幕在线有码观看,激情大尺度同志小说,波多野结衣博客,与亲女洗澡时伦了2次,国产三级在线一区二区

您好，歡迎來(lái)到上海士研管理咨詢(xún)有限公司
產(chǎn)業(yè)峰會(huì) 演講局 專(zhuān)家智庫(kù)服務(wù) 峰會(huì)活動(dòng)服務(wù) 整合營(yíng)銷(xiāo)服務(wù)
  • 產(chǎn)業(yè)峰會(huì)：
    以專(zhuān)業(yè)團(tuán)隊(duì)對(duì)產(chǎn)業(yè)和市場(chǎng)客觀詳實(shí)地調(diào)研為前提，擁有戰(zhàn)略性、系統(tǒng)性、全球性的基因，匯集了領(lǐng)導(dǎo)者關(guān)注的熱點(diǎn)話題與領(lǐng)袖代表，為您提供“一站式”的對(duì)話、分享、社交平臺(tái)!
  • 演講局：
    致力于為全球企業(yè)和機(jī)構(gòu)提供主題演講家、高管大師班、董事會(huì)顧問(wèn)，每項(xiàng)服務(wù)都提供了一種更深入、更具互動(dòng)性的體驗(yàn)，尤其是針對(duì)較小的精選受眾和關(guān)鍵個(gè)人。我們擁有最具影響力的商業(yè)領(lǐng)袖和頂級(jí)專(zhuān)家的資源，他們是各自領(lǐng)域的最杰出的代表。我們的團(tuán)隊(duì)由經(jīng)驗(yàn)豐富的演講和活動(dòng)經(jīng)理組成，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 專(zhuān)家智庫(kù)服務(wù)：
    中國(guó)領(lǐng)先的行業(yè)專(zhuān)家知識(shí)信息服務(wù)供應(yīng)商，為需要專(zhuān)業(yè)洞見(jiàn)的商業(yè)決策者匹配具有一手經(jīng)驗(yàn)的行業(yè)專(zhuān)家，助力他們以更加明確的目標(biāo)和堅(jiān)定的信心做出決策。我們有60萬(wàn)余名專(zhuān)家顧問(wèn)遍布二十多個(gè)行業(yè)，而且每天還在增加！
  • 峰會(huì)活動(dòng)服務(wù)：
    致力于成為全球最專(zhuān)業(yè)的產(chǎn)業(yè)峰會(huì)活動(dòng)提供商，為企業(yè)和機(jī)構(gòu)的產(chǎn)業(yè)性峰會(huì)活動(dòng)提供一站式專(zhuān)業(yè)服務(wù)，包括調(diào)研策劃、定制邀請(qǐng)、營(yíng)銷(xiāo)推廣、運(yùn)營(yíng)組織、項(xiàng)目管理、直播與數(shù)字化會(huì)議等，每項(xiàng)服務(wù)都由經(jīng)驗(yàn)豐富的專(zhuān)業(yè)團(tuán)隊(duì)匹配長(zhǎng)期沉淀的產(chǎn)業(yè)資源予以卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 整合營(yíng)銷(xiāo)服務(wù)：
    致力于成為全球領(lǐng)先的2B營(yíng)銷(xiāo)服務(wù)機(jī)構(gòu)，聚焦產(chǎn)業(yè)高端活動(dòng)、內(nèi)容、渠道的建設(shè)與沉淀，為客戶提供一站式整合營(yíng)銷(xiāo)解決方案，助力企業(yè)線上線下獲客與品牌筑造。我們深信專(zhuān)業(yè)團(tuán)隊(duì)匹配產(chǎn)業(yè)資源帶來(lái)卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
會(huì)議贊助商
4
2023 - 08 - 23
點(diǎn)擊次數(shù):
泓博醫(yī)藥(股票代碼：301230)成立于2007年，總部位于上海，致力于為全球醫(yī)藥客戶提供新藥研發(fā)和商業(yè)化生產(chǎn)一站式綜合服務(wù)，涵蓋藥物發(fā)現(xiàn)、制藥工藝的研究開(kāi)發(fā)以及原料藥、中間體的商業(yè)化生產(chǎn)等領(lǐng)域。目前，公司擁有超過(guò)22000平方米研發(fā)實(shí)驗(yàn)室(37000平方米臨床前新藥研發(fā)基地在建中）以及60000平方米生產(chǎn)基地，研發(fā)技術(shù)人員占比超63%。在16年的征途中,泓博醫(yī)藥通過(guò)特有的“CRO”和“CDMO業(yè)務(wù)模式,構(gòu)建了全方位綜合性技術(shù)平臺(tái),為國(guó)內(nèi)外客戶的新藥研發(fā)提供了有力支撐。 PharmaResources（StockCode：301230.SZ）was founded in 2007 and is headquartered in Shanghai. The company is committed to providing comprehensive services for global pharmaceutical clients, including new drug research and development and commercial production, covering areas such as drug discovery, pharmaceutical process research and development, as well as commercial production of active pharmaceutical ingredients and intermediates. Currently, the company has over 22,000 square meters of R&D laboratories (with a 37,000 square meter preclinical new drug R&D base under construction) and a 60,000 square meter production base. R&D technical personnel account for over 63% of the workforce. Over the course of its 16-year journey, PharmaResources has established a comprehensive technical platform through its unique 'CRO' and 'CDMO' business models, providing strong support for the new drug development of domestic and international clients.
5
2023 - 08 - 23
點(diǎn)擊次數(shù):
藥明康德（股票代碼：603259.SH/2359.HK）為全球生物醫(yī)藥行業(yè)提供一體化、端到端的新藥研發(fā)和生產(chǎn)服務(wù)，在亞洲、歐洲、北美等地均設(shè)有運(yùn)營(yíng)基地。藥明康德通過(guò)獨(dú)特的“CRDMO”和“CTDMO”業(yè)務(wù)模式，不斷降低研發(fā)門(mén)檻，助力客戶提升研發(fā)效率，為患者帶來(lái)更多突破性的治療方案，服務(wù)范圍涵蓋化學(xué)藥研發(fā)和生產(chǎn)、生物學(xué)研究、臨床前測(cè)試和臨床試驗(yàn)研發(fā)、細(xì)胞及基因療法研發(fā)、測(cè)試和生產(chǎn)等領(lǐng)域。2022年，藥明康德被MSCI評(píng)為ESG（環(huán)境、社會(huì)及管治）AA級(jí)。目前，公司的賦能平臺(tái)正承載著來(lái)自全球30多個(gè)國(guó)家的6000多家合作伙伴的研發(fā)創(chuàng)新項(xiàng)目，致力于將更多新藥、好藥帶給全球病患，早日實(shí)現(xiàn)“讓天下沒(méi)有難做的藥，難治的病”的愿景。As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that 'every drug can be made and every disease can be treated.'
6
2023 - 08 - 23
點(diǎn)擊次數(shù):
太倉(cāng)市沿江臨滬，地處沿海經(jīng)濟(jì)帶和長(zhǎng)三角經(jīng)濟(jì)圈核心位置，距離上海張江藥谷和蘇州BioBAY均只需1小時(shí)車(chē)程，高鐵900秒抵達(dá)上海虹橋站，2027年地鐵接軌上海。太倉(cāng)港是長(zhǎng)江外貿(mào)第一大港，位列全球集裝箱港口第22位。太倉(cāng)將生物醫(yī)藥作為重點(diǎn)發(fā)展的戰(zhàn)略性新興產(chǎn)業(yè)，圍繞新藥研發(fā)生產(chǎn)、醫(yī)療器械、醫(yī)藥服務(wù)外包等領(lǐng)域，已集聚了昭衍新藥、康乃德生物、中美冠科、含光微納、思納福、賽業(yè)模式生物、依科賽生物等400余家生物醫(yī)藥企業(yè)，形成了完善的上下游產(chǎn)業(yè)鏈。Taicang is not only borders Shanghai but also faces the Yangtze River, located in the core position of the coastal economic belt and the Yangtze River Delta economic circle. It is only about an one-hour drive both from Shanghai Zhangjiang Pharmaceutical Valley and Suzhou BioBAY and 900 seconds from Taicang railway station to Shanghai Hongqiao railway station. In additon, the subway will be connected to Shanghai in 2027. Taicang port is the largest foreign trade port on the Yangtze River and the 22th in the global container ports. Taicang prioritized Biomedical as a strategic industry, with a focus on new medical development and production, medical devices, and pharmaceutical outsourcing services. The biomedical industry has gathered nearly 400 biomedical enterprises in the city, including Joinn Laboratories, Connect Biopharmaceuticals, Crown Bioscience, HiComp Microtech, Sinafu Medical Technology, Cyagen Biosciences, ExCell Biotech and other potential biomedical enterprises, Already formed a complete industrial chain.
微信公眾號(hào)
領(lǐng)導(dǎo)者網(wǎng)絡(luò)APP
Copyright ?2005 - 2017上海士研管理咨詢(xún)有限公司
犀牛云提供企業(yè)云服務(wù)